Last updated: April 30, 2026
What is DILANTIN-30 and what is its regulatory posture?
DILANTIN-30 is the 30 mg formulation of phenytoin (Dilantin). Phenytoin has long-established use in epilepsy (especially focal seizures and generalized tonic-clonic seizures) and has a deep history of generic penetration in most major markets. In practice, “DILANTIN-30” appears as a branded strength/formulation identifier within the phenytoin product ecosystem, not as a standalone new molecular entity.
Because the drug is a long-commercialized small molecule, the market is shaped primarily by:
- Brand-to-generic substitution dynamics
- Formulation and supply continuity
- Patent/market exclusivity status at product level (strength/formulation-specific), rather than molecule-level innovation
Is there active clinical trial activity specific to DILANTIN-30?
No dataset-wide, strength-specific clinical trial activity can be reliably attributed to “DILANTIN-30” based on available indexing conventions for phenytoin products. Clinical trial records that exist for phenytoin typically describe:
- the active ingredient (phenytoin) rather than a branded “30 mg” strength, and/or
- formulation-level comparisons (e.g., extended-release vs immediate-release), which are not consistently mapped to “DILANTIN-30” labels in trial registries.
Given that constraint, a clinical-trials update for “DILANTIN-30” cannot be completed with integrity to registry-level specificity.
What does the market look like for phenytoin (and where does DILANTIN-30 fit)?
Demand drivers
Phenytoin demand is driven by:
- Persistent clinical use in seizure management where alternatives exist and remain standard-of-care in certain settings
- Institutional procurement patterns (hospital formularies and neurology/epilepsy service lines)
- Competition from other antiseizure medications (ASMs), especially newer agents with improved tolerability and dosing convenience
Supply and pricing reality
The phenytoin market is structurally exposed to:
- Generic entry and continuous price pressure
- Formulary switching toward lower-cost products
- Manufacturing and distribution stability as a key determinant of real-world continuity
Segment mapping for “30 mg”
“30 mg” typically maps to product size/strength within an oral solid inventory rather than a distinct pharmacologic category. Commercial outcomes usually track:
- overall phenytoin demand, and
- share shifts driven by procurement, contracting, and interchangeability.
How should you model market share and revenue for DILANTIN-30?
A realistic projection approach treats DILANTIN-30 as a strength-level SKU within a larger phenytoin franchise rather than a standalone therapeutic innovation.
A practical revenue model uses three layers:
- Market TAM (phenytoin oral solid, treated as a pooled class)
- Determine total phenytoin unit demand in target geographies (public IMS-type or national data series).
- Convert units to revenue using weighted average net prices (brand vs generic mix).
- SKU share (DILANTIN-30 strength penetration)
- Allocate DILANTIN-30 share based on:
- prescriber/administered dose patterns,
- pharmacy stocking preferences,
- tender/contracts in institutional channels.
- Net price trajectory
- Assume price compression from:
- generic substitution,
- reimbursement pressure,
- contracting dynamics,
- periodic brand-specific promotional cycles (if applicable).
Scenario framework (used for projection)
- Base case: steady phenytoin class demand with modest share drift due to conversion to other ASMs; DILANTIN-30 retains a stable strength-level mix.
- Downside case: faster ASM displacement in institutional formularies and higher generic share retention.
- Upside case: procurement continuity and favorable contracting keep DILANTIN-30 SKU share stable while phenytoin class declines slower than expected.
What is the likely clinical development path affecting DILANTIN-30?
For long-established phenytoin products, development typically focuses on:
- Bioequivalence and formulation refinement (to support regulated product changes)
- Regulatory submissions rather than large, hypothesis-driven Phase 2/3 programs for the active ingredient
- Subgroup evidence tied to manufacturing scale, excipients, stability, and interchangeability
This market pattern favors regulatory lifecycle execution over classic “clinical pipeline” visibility.
Market projection: what growth or decline is plausible for a 30 mg phenytoin SKU?
Because DILANTIN-30 is a strength-level branded identifier within a generic-dominated active ingredient, the projection should be framed as decline/flatness rather than growth unless there is a specific, documentable exclusivity event at the product level.
A base projection template for DILANTIN-30 (per year) would use:
- Units: stable-to-declining (driven by phenytoin class contraction and ASM displacement)
- Net price: downward due to generic competition and contracting
- Revenue: declines at a slower pace than units if brand holds value in certain channels, or declines similarly if net price compresses quickly
Competitive landscape: what other ASMs influence phenytoin demand?
Phenytoin competes for antiseizure budgets and prescribing attention against:
- newer ASMs with broader convenience profiles,
- improved tolerability and fewer monitoring burdens (phenytoin requires therapeutic drug monitoring due to nonlinear kinetics in many contexts),
- and payer policies that increasingly encourage cost-effective ASM selection.
In practice, the displacement pressure is a key driver for phenytoin class shrinkage across many markets, while real-world persistence remains in certain patient populations and institutional protocols.
Key operational implications for R&D and investment
For DILANTIN-30 specifically, the actionable lens is not “build a pipeline,” it is “manage the product lifecycle”:
- Regulatory execution for formulation/packaging changes and supply continuity
- Contracting strategy (tenders, hospital formularies, pharmacy buying groups)
- Defensibility via execution, not IP (where molecule-level IP has expired)
That is consistent with how mature, generic-exposed ASMs behave in commercial terms.
Key Takeaways
- DILANTIN-30 is a strength-level phenytoin product, and the market behaves like a mature, generic-dominated ASM rather than a novel therapeutic platform.
- Strength-specific clinical trials for “DILANTIN-30” are not reliably attributable from standard registry indexing conventions for phenytoin.
- Market projection should be modeled as SKU share within a shrinking or flat class, with revenue driven primarily by net price and procurement mix, not clinical efficacy differentiation.
- Competitive displacement by newer ASMs is the dominant macro driver; operational performance (supply, contracting, formulary retention) determines whether DILANTIN-30 tracks class decline or underperforms.
FAQs
-
Is DILANTIN-30 a new drug?
No. It is a phenytoin strength/product label within the established phenytoin asset category.
-
Are there Phase 3 trials for DILANTIN-30?
No registry-level, strength-specific Phase 3 activity can be stated for “DILANTIN-30” without conflating it with generic phenytoin trials.
-
What determines DILANTIN-30 sales in practice?
Hospital and pharmacy contracting, formulary status, and the net price versus generics, because phenytoin is mature and widely available.
-
Does clinical monitoring affect market uptake?
Yes. Phenytoin’s therapeutic drug monitoring needs and nonlinear kinetics shape prescribing patterns and favor newer ASMs for many patients.
-
What should investors watch for next?
Product supply stability, contracting wins, and any product-level regulatory or exclusivity events that can affect SKU-level net pricing.
References
[1] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-01).
[2] ClinicalTrials.gov. Phenytoin search results and study records. (Accessed 2026-05-01).
[3] World Health Organization. WHO Model List of Essential Medicines (antiseizure medicines and related context). (Accessed 2026-05-01).
